The PennZone

  • Home
  • Health
  • Business
  • Non-profit
  • Technology
  • Travel
  • Music
  • Construction
  • Books

Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO
The PennZone/10289596

Trending...
  • Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV
  • The New Monaco of the South (of Italy)
  • PA Golf Cart World Launches NEV Pre-Inspection & Compliance Service for 2026
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.

Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.

"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."

More on The PennZone
  • Syntax of Sorrow: An Exhibition Examining Synthetic Affliction in the Age of Artificial Intelligence
  • Waarom brand mentions in ChatGPT steeds belangrijker worden
  • Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
  • At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
  • Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association

Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.

Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.

"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."

More on The PennZone
  • Insight Holistic Imaging Introduces In-LightN Advanced Thermography - New Personalized Wellness Scr
  • TrueNorth Wellness Services Welcomes a New CEO
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
  • Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use

Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.

Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.

With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • How Democrats Made Healthcare More Expensive in 2026
  • Inkdnylon Launches Bilingual Ask Inkdnylon Platform
  • JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
  • ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
  • Mitchell Sipus Releases New Dance Single "Can U"
  • FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
  • The New Monaco of the South (of Italy)
  • OctoNerv Completes Functional Prototype of Electronic Breast Nipple Implant (EBNI)
  • Zivra AI Launches Real-Time Business Health and Financial Intelligence for SMEs
  • Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
  • PA Golf Cart World Launches NEV Pre-Inspection & Compliance Service for 2026
  • Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
  • Are You Hiring The Right Heater Repair Company in Philly?
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board
  • Appliance EMT Expands Professional Appliance Repair Services to Hartford, Connecticut

Popular on PennZone

  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 229
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 212
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • God's Meal Barrel Combats the Increased Community Need in 2025
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri

Similar on PennZone

  • Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
  • RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
  • $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
  • MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
  • Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
  • How Democrats Made Healthcare More Expensive in 2026
  • Inkdnylon Launches Bilingual Ask Inkdnylon Platform
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us